Inhibikase Therapeutics (IKT) Receivables - Net (2021 - 2023)

Inhibikase Therapeutics (IKT) has 3 years of Receivables - Net data on file, last reported at $79604.0 in Q2 2023.

• On a quarterly basis, Receivables - Net rose 1114.96% year-over-year to $79604.0 in Q2 2023; TTM through Jun 2023 was $79604.0, a 1114.96% increase from a year earlier, with the FY2022 full-year figure at $39881.0, down 63.79% from the prior year.
• Receivables - Net for Q2 2023 stood at $79604.0, up from $64521.0 in the prior quarter.
• Over the last five years, Receivables - Net for IKT reached as high as $586581.0 in Q2 2021 and fell as low as $6552.0 in Q2 2022.
• Historically, Receivables - Net has averaged $149935.4 across 3 years, with a median of $72062.5 in 2023.
• Across the five-year window, Receivables - Net tumbled 98.88% in 2022 and jumped 1114.96% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $110141.0 in 2021, then tumbled by 63.79% to $39881.0 in 2022, then jumped by 99.6% to $79604.0 in 2023.
• Per Business Quant data, the three most recent Receivables - Net figures were $79604.0 in Q2 2023, $64521.0 in Q1 2023, and $39881.0 in Q4 2022.